StockData
Inhibrx Biosciences, Inc. logo

Inhibrx Biosciences, Inc. (INBX) stock

INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$74.18−3.48 (-4.48%)

Close on Nov 17, 2026Market cap $1.09BP/E –Yield –

Inhibrx Biosciences price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Inhibrx Biosciences's price to sales ratio was 348.3× on Sep 30, 2025, against 334.4× a year earlier. Over the last 4 years it ranged from 13.6× to 390.0×, with a median of 50.4×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2025Sep 30, 2025348.3×+219.7
2024Dec 31, 2024128.6×−153.4
2023Oct 31, 2023281.9×+231.5
2022Dec 30, 202250.4×−7.5
2021Dec 31, 202157.9×+28.0
2020Dec 31, 202030.0×–

More Inhibrx Biosciences figures

See a number that looks wrong?